Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CUREfilm Canna** is an oral thin film (OTF) formulation developed by CURE Pharmaceutical containing THC and CBD, utilizing the proprietary **CUREform™** platform with micro-encapsulation to enhance bioavailability, solubility, and absorption of these fat-soluble cannabinoids, which typically suffer from poor oral uptake and first-pass metabolism. The technology enables sublingual or buccal delivery for rapid onset, precise dosing, and improved patient compliance, with studies on similar CBD OTF showing ~3x higher Cmax and faster Tmax versus soft gels. It is part of CURE's clinical pipeline targeting unmet needs in cannabinoid therapeutics, with partnerships like Canopy Growth for global cannabis extract applications and DEA registration for manufacturing Schedule 1 cannabinoid products.[1][2][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CUREfilm Canna.